Modus Therapeutics strengthens its Board of Directors with two key appointments, Stig Løkke Pedersen and Karin Knobe.

Stig Løkke Pedersen, an experienced life science industry veteran with more than 30 years’ experience, has been appointed Chairman of the Board. Mr Løkke Pedersen worked for 20 years at H. Lundbeck A/S, and served as the Group’s Chief Commercial Officer between 2005 and 2011. He currently serves as the chairman of the Board in SSI Diagnostica A/S, Moksha8 Ltd, Transmedica A/S and Nuevolution AB. He is a member of the Board in Skybrands A/S, BroenLab A/S and Index Pharmaceuticals AB. Mr Pedersen is also an operating partner in the Danish private equity fund Catacap A/S.

Dr Karin Knobe joins the Board as a Non-executive Director, bringing a wealth of pharmaceutical development experience. Dr Knobe is currently Head of Rare Blood Disorders Development, Sanofi, Global; and Associate Professor at Lund University. Prior to joining Sanofi, she was Vice President, Head of Clinical Development at Sobi and before that Vice President, Medical and Science, Haemophilia at Novo Nordisk. Dr Knobe is an expert in haemostasis and orphan drug development.

“I am extremely pleased to welcome both Stig and Karin to the Modus Therapeutics Board of Directors. They bring a wealth of experience and highly relevant skills gained over many years in the industry. Their expertise will complement the skills of our other Board members and our management team, and I am looking forward to working with them as we  plan for the results from our global randomized Phase II clinical trial assessing sevuparin for the management of acute vaso-occlusive crisis in patients with sickle cell disease, which are due in mid-2019,” said Ellen K Donnelly, PhD, CEO of Modus Therapeutics.